CASI Pharmaceuticals, Inc. (CASI)

Market Cap	39.88M
Revenue (ttm)	22.06M
Net Income (ttm)	-30.97M
Shares Out	15.05M
EPS (ttm)	-2.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	76,852
Open	2.720
Previous Close	2.790
Day's Range	2.650 - 2.820
52-Week Range	2.050 - 8.190
Beta	0.55
Analysts	Strong Buy
Price Target	6.00 (+126.42%)
Earnings Date	Nov 15, 2024

About CASI

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People’s Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company’s other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-FcγRIIB ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 11, 1996
• Employees: 176
• Stock Exchange: NASDAQ
• Ticker Symbol: CASI
• Website: https://www.casipharmaceuticals.com

Financial Performance

In 2023, CASI Pharmaceuticals's revenue was $33.88 million, a decrease of -21.41% compared to the previous year's $43.11 million. Losses were -$26.96 million, -34.27% less than in 2022.

Analyst Forecast

According to one analyst, the rating for CASI stock is "Strong Buy" and the 12-month stock price forecast is $6.0.

Price Target

$6.0

(126.42% upside)

Analyst Consensus: Strong Buy